IMPACT OF SMOKING STATUS ON CLINICAL OUTCOMES WITH PRASUGREL VERSUS CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROMES MANAGED WITHOUT revascularization: INSIGHTS FROM THE TRILOGY ACS TRIAL

Active smoking is associated with increased thrombosis risk and enhanced efficacy of clopidogrel therapy vs placebo. Prasugrel metabolism is not influenced by smoking and has superior pharmacodynamic efficacy, but its relationship to clinical outcomes has not been evaluated in medically managed ACS